Phase II Study of Glofitamab, Poseltinib and Lenalidomide in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glofitamab (Primary) ; Lenalidomide (Primary) ; Poseltinib (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Sponsors Roche

16 Dec 2024 Status changed from recruiting to active, no longer recruiting.
04 Jun 2024 Interim results of evaluating glofitamab combined with poseltinib and lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
15 Jun 2023 Initial results (n=6) assessing the efficacy and safety of glofitamab in combination with lenalidomide and poseltinib in patients with relapsed/refractory diffuse B cell lymphomas, presented at the 28th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com